Connect with us

Hi, what are you looking for?


This biotech stock could double from here: Goldman Sachs

vir stock could double from here goldman sachs

Vir Biotechnology Inc (NASDAQ: VIR) jumped nearly 10% this morning after a Goldman Sachs analyst turned super bullish on the clinical-stage immunology company.

Vir stock has upside to $53 a share

On Tuesday, Paul Choi upgraded the biotech stock to “buy” and raised his price target significantly to $53 that represents about a 100% upside from here.

The bullish call is based primarily on VIR-2482 – the company’s new, more potent vaccine for flu. His research note reads:

VIR will report VIR-2482 data in mid-2023, which we expect to show meaningfully better efficacy than currently approved and rival pipeline-stage flu vaccines and drive material upward revisions to consensus estimates.

The Goldman Sachs analyst dubbed Vir stock a compelling risk-reward now that it’s been cut in more than half over the pasts 24 months.

How is VIR-2482 different than rivals?

VIR-2482 targets the Influenza Hemagglutinin (HA) stem that would potentially help sustain its efficacy in flu season every year since the said region is highly conserved. Choi added:

While previous antibody challenge studies have failed, modifications to VIR-2482 that result in increased potency (ADCC) and a longer half-life should provide sufficient serum coverage well above EC90 over a flu season.

The Nasdaq-listed firm is expected to lose 4 cents a share this quarter – well below $3.92 per share it “earned” a year ago. It’s scheduled to report its quarterly results later this week.

But the Goldman Sachs analyst remains convinced that the new vaccine could unlock a post-COVID rally in the Vir stock in the coming months.

The post This biotech stock could double from here: Goldman Sachs appeared first on Invezz.

You May Also Like


Inflation appears to be on the decline. The Personal Consumption Expenditures Price Index (PCEPI), which is the Federal Reserve’s preferred measure of inflation, grew...


Mimiq, Inc is announcing today the launch of their new product, Mimiq Track, at CES as part of their latest product line to operate...


On this week’s edition of Stock Talk with Joe Rabil, Joe looks at the longer-term picture for stocks like AAPL, TSLA, and more. He...

Latest News

Kevin McCarthy’s difficult road to becoming House speaker ended early Saturday morning after Republicans appeared to have miscounted the number of votes they needed...

Disclaimer:, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2023